SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending following a trading halt prompted by the news that its drug tovecimig did not meet the overall survival secondary endpoint in a Phase 2/3 study. The community is actively debating the implications for the company's regulatory path and future BLA filing, with significant skepticism regarding the trial design and statistical outcomes.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is trending following positive interim Phase 2a results for ORKA-001 in psoriasis, which hit its primary endpoint and showed potential for annual dosing. The community is actively debating the company's long-term valuation compared to sector peers and monitoring potential dilution as the firm moves toward larger late-stage trials.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy (GLND) is surging as community sentiment centers on a major drilling partnership with Halliburton for a 2026 campaign in the Jameson Land Basin, which investors view as a pivotal validation of the company's Arctic oil and mineral assets. Discussions are heavily focused on the stock's low float, extreme short interest, and the potential for a significant squeeze amid heightened global interest in energy security.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to a significant revenue outlook miss for the upcoming quarter and broader memory supply constraints that are pressuring smartphone handset sales. Community sentiment is deeply divided, with many debating the impact of these headwinds versus the potential for long-term growth through AI-powered smartphone chips, upcoming automotive design wins, and aggressive stock buyback programs.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is drawing significant investor focus as the stock navigates a challenging consumer environment, with community discourse centered on whether its recent earnings and profitability metrics signal a buying opportunity or further volatility. While some investors remain bullish on the company's long-term franchise stability and dividend growth, many are actively debating the impact of inflationary pressures and evolving delivery competition on its competitive moat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WRD . American  media and analysts continue to deceive investors on the Wrd story. I watched a utube  video over the weekend that claimed Pony was the better investment because they sign asset light contracts with business partners..Claimed Weride owns and maintains all fleet agreements which is extremely asset heavy. Absolutely a big lie !!!!  Makes for bargain stock price as facts will prevail

Niels

Marc

StockTwits for iOS

WeRide Inc. - ADR

 . American  media and analysts continue to deceive investors on the Wrd story. I watched a utube  video over the weekend that claimed Pony was the better investment because they sign asset light contracts with business partners..Claimed Weride owns and maintains all fleet agreements which is extremely asset heavy. Absolutely a big lie !!!!  Makes for bargain stock price as facts will prevail